| Primary |
| Product Used For Unknown Indication |
29.6% |
| Renal Cancer |
22.9% |
| Renal Cell Carcinoma |
15.1% |
| Metastatic Renal Cell Carcinoma |
4.4% |
| Sarcoma |
4.4% |
| Renal Cancer Metastatic |
3.8% |
| Hypertension |
3.0% |
| Soft Tissue Cancer |
2.9% |
| Neoplasm Malignant |
2.7% |
| Malignant Urinary Tract Neoplasm |
2.4% |
| Malignant Soft Tissue Neoplasm |
1.4% |
| Leiomyosarcoma |
1.3% |
| Thyroid Cancer |
1.2% |
| Pain |
1.2% |
| Lung Neoplasm Malignant |
0.8% |
| Non-small Cell Lung Cancer |
0.7% |
| Neoplasm |
0.6% |
| Breast Cancer |
0.6% |
| Nausea |
0.5% |
| Diabetes Mellitus |
0.4% |
|
| Death |
26.8% |
| Nausea |
8.5% |
| Vomiting |
7.9% |
| Diarrhoea |
6.7% |
| Drug Ineffective |
6.6% |
| Weight Decreased |
6.4% |
| Fatigue |
6.0% |
| Hypertension |
3.6% |
| Disease Progression |
3.6% |
| Blood Pressure Increased |
2.8% |
| Malignant Neoplasm Progression |
2.7% |
| Hospitalisation |
2.7% |
| Toxicity To Various Agents |
2.7% |
| Malaise |
2.6% |
| Neoplasm Malignant |
2.2% |
| Rash |
1.8% |
| Pain |
1.7% |
| Adverse Drug Reaction |
1.6% |
| Hair Colour Changes |
1.6% |
| Renal Cancer |
1.6% |
|
| Secondary |
| Product Used For Unknown Indication |
21.2% |
| Soft Tissue Cancer |
14.5% |
| Leiomyosarcoma |
9.7% |
| Renal Cancer |
6.5% |
| Spindle Cell Sarcoma |
5.4% |
| Myxofibrosarcoma |
4.8% |
| Hypertension |
4.3% |
| Renal Cell Carcinoma |
4.3% |
| Liposarcoma |
3.8% |
| Undifferentiated Sarcoma |
3.8% |
| Gastric Ulcer |
3.2% |
| Metastatic Renal Cell Carcinoma |
3.2% |
| Synovial Sarcoma |
3.2% |
| Neoplasm |
2.7% |
| Constipation |
1.6% |
| Extra-osseous Ewing's Sarcoma |
1.6% |
| Pain |
1.6% |
| Prostate Cancer |
1.6% |
| Sarcoma |
1.6% |
| Anaemia |
1.3% |
|
| Vomiting |
12.2% |
| Weight Decreased |
12.2% |
| White Blood Cell Count Decreased |
11.1% |
| Platelet Count Decreased |
10.0% |
| Death |
8.9% |
| Pancytopenia |
5.6% |
| Drug Ineffective |
4.4% |
| Haemolytic Uraemic Syndrome |
3.3% |
| Hypoglycaemia |
3.3% |
| Malaise |
3.3% |
| Rash |
3.3% |
| Thrombocytopenia |
3.3% |
| Urethritis |
3.3% |
| Diarrhoea |
2.2% |
| Nausea |
2.2% |
| Pneumothorax |
2.2% |
| Polycythaemia |
2.2% |
| Pyrexia |
2.2% |
| Renal Failure Acute |
2.2% |
| Skin Fragility |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
23.1% |
| Renal Cancer Metastatic |
12.1% |
| Renal Cancer |
7.7% |
| Renal Cell Carcinoma |
7.7% |
| Pain |
6.6% |
| Glioblastoma Multiforme |
5.5% |
| Nausea |
5.5% |
| Glioma |
4.4% |
| Bone Disorder |
3.3% |
| Metastatic Renal Cell Carcinoma |
3.3% |
| Prophylaxis |
3.3% |
| Rectal Cancer |
3.3% |
| Analgesic Therapy |
2.2% |
| Bladder Cancer |
2.2% |
| Bone Cancer |
2.2% |
| Malignant Soft Tissue Neoplasm |
2.2% |
| Metastases To Bone |
2.2% |
| Appetite Disorder |
1.1% |
| Arrhythmia |
1.1% |
| Breakthrough Pain |
1.1% |
|
| Death |
20.7% |
| Neoplasm Malignant |
10.3% |
| Gingival Recession |
6.9% |
| Rash |
6.9% |
| Adverse Drug Reaction |
3.4% |
| Asthenia |
3.4% |
| Chest Pain |
3.4% |
| Dementia |
3.4% |
| Diarrhoea |
3.4% |
| Exercise Tolerance Decreased |
3.4% |
| Gait Disturbance |
3.4% |
| Glioblastoma Multiforme |
3.4% |
| Hepatic Neoplasm |
3.4% |
| Insomnia |
3.4% |
| Intestinal Perforation |
3.4% |
| Malignant Neoplasm Progression |
3.4% |
| Nausea |
3.4% |
| Neoplasm Progression |
3.4% |
| Neutropenia |
3.4% |
| Osteonecrosis Of Jaw |
3.4% |
|
